Panacea-ml

Explainable-AI Platform to Streamline Clinical Trial Design

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in August 2022 by Prof. Boaz Lerner, Panacea-ml operates with 1–10 employees. The company has secured funding across one round from Sanara Ventures and the Israel Innovation Authority. In November 2022, Panacea-ml received funding from Sanara Ventures and the Israel Innovation Authority.

Business overview

Panacea-ml is a Health Tech & Life Sciences company that develops an Explainable AI platform designed to streamline clinical trial design. Spun out of Ben Gurion University, the company's cutting-edge SaaS platform leverages proprietary explainable AI and causal discovery theory to uncover causal relationships between clinical markers, disease progression, and drug responses. This technology aims to de-risk, accelerate, and optimize trial designs, providing transparent and clinically relevant insights. Panacea-ml targets the data analytics and design segment of the clinical trial market, focusing on high-failure areas such as neurology and immuno-metabolic diseases.

Strategic signal

In July 2024, Panacea-ml completed the PharmStars accelerator program, marking its position as the first Israeli startup to graduate from the program. This achievement signals strong validation of Panacea-ml's Explainable AI platform within the pharmaceutical industry, indicating its readiness for broader market adoption and potential for strategic partnerships in digital health.

Log in to access full profile

Company Intelligence Q&A

When was Panacea-ml founded?
Panacea-ml was founded in August 2022 by Prof. Boaz Lerner.
What is Panacea-ml's primary focus?
Panacea-ml focuses on disrupting clinical development with its Explainable AI platform, aiming to streamline clinical trial design and improve success rates by providing transparent, clinically-relevant insights into trial outcomes.
Which accelerator program did Panacea-ml recently complete?
In July 2024, Panacea-ml completed the PharmStars accelerator program, becoming the first Israeli startup to graduate from it.
What was a key funding event for Panacea-ml?
In November 2022, Panacea-ml received funding from Sanara Ventures and the Israel Innovation Authority in a Pre-Seed round.
What problem does Panacea-ml's technology address in clinical trials?
Panacea-ml addresses the main causes of clinical trial failures, such as patient population heterogeneity, poor trial design, and biostatistics limitations, which are responsible for over 85% of non-drug-related trial failures.
Log in to access full profile